Abstract
In past decades epidemiological studies have identified several risk factors for early-onset coronary artery disease (CAD1–3). Among these factors disorders of lipoprotein metabolism have a leading role. The PROspective CArdiovascular Minister (PROCAM) study, carried out in the northwest of Germany, has demonstrated that among all single- parameter biochemical markers the concentration of plasma lipids has the highest predictive value.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Miller NE, Forde OH, Thelle DS, Mjos OD. The Tromso heart-study. High density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1977; 965–68.
Castellu WP, Garrison RJ, Wilson PWF, Abbott TD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986; 256: 2835–8.
Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992; 70: 733–7.
Sing CF, Moll PP. Genetics of atherosclerosis. Annu Rev Genet. 1990; 24: 171–87.
Brown MS, Goldstein JL. The hyperlipoproteinemias and other disorders of lipid metabolism. In: Isselbacher KJ, Adams RD, Braunwald E, Petersdorf RG, Wilson JD, editors. Harrison’s principles of internal medicine, 12th ed. New York: McGraw-Hill; 1991.
Rust S, Funke H, Assmann G. Analysis of pooled samples from nearly 10000 individuals, with mutagenically separated PCR (MS-PCR) shows a significant overrepresentation of familial defective apoB-100 in coronary artery disease patients. Circulation, Suppl. 1992; 86: 420.
Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutation. 1992; 1: 445–66.
Innerarity TL, Mahley RW, Weisgraber KH, et al. Familial defective apolipoprotein B-100; a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res. 1990; 31: 1337–49.
Pullinger CR, Hennessy LK, Chatterton JE, et al. Familial ligand-defective apolipoprotein B: identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest. 1995; 95: 1225–34.
Ludwig EH, Blackhart BD, Pierotti VR, et al. DNA sequence of the human apolipoprotein B gene. DNA. 1987; 6: 363–72.
Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harbor Symp Quant Biol. 1986; 51: 263–73.
Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory system (ARMS). Nucl Acids Res. 1989; 17: 2503–16.
Rust S, Funke H, Assmann G. Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. Nucl Acids Res. 1993; 21: 3623–9.
Assmann G, von Eckardstein A, Funke H. High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations. Circulation, Suppl. 1993; 87: 28–34.
Funke H, von Eckardstein A, Pritchard PH, et al. Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease. J Clin Invest. 1993; 91: 677–83.
Rômling R, von Eckardstein A, Funke H, et al. A nonsense mutation in the apolipoprotein A-I gene is associated with high density lipoprotein deficiency and periorbital xanthelasmas. Arterioscler Thromb. 1994; 14: 1915–22.
Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res. 1992; 33: 447–54.
Funke H, Wiebusch W, Fuer L, etal. Identification of mutations in the cholesterol ester transfer protein in Europeans with elevated high density lipoprotein cholesterol. Circulation. 1994; 90: 1–241.
Reymer PWA, Gagné E, Groenemeyer BE, etal. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nature Genet. 1995; 10 (In press).
Funke H, Assmann G. The lowdown on lipoprotein lipase. Nature Genet. 1995; 10 (In press).
Mailly F, Tugrul Y, Reymer PWA, et al. A common variant in the gene for lipoprotein lipase (Asp9-Asn): functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler Thromb Vascul Biol. 1995; 15: 468–78.
Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest. 1991; 87: 2153–61.
Cohen JC, Chiesa G, Hobbs HH. Sequence polymorphism in the apolipoprotein(a) gene. Evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels. J Clin Invest. 1993; 91: 1630–6.
Sandholzer C, Saha N, Kark JD, et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb. 1992; 12: 1214–26.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Kluwer Academic Publishers
About this chapter
Cite this chapter
Funke, H., Wiebusch, H., Rust, S., Assmann, G. (1995). Molecular genetics approach to lipoprotein metabolism disorders. In: Assmann, G. (eds) HDL Deficiency and Atherosclerosis. Developments in Cardiovascular Medicine, vol 174. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-6585-3_1
Download citation
DOI: https://doi.org/10.1007/978-94-011-6585-3_1
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-011-6587-7
Online ISBN: 978-94-011-6585-3
eBook Packages: Springer Book Archive